Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy
Capsida Biotherapeutics ('Capsida') today announced the presentation of new non-human primate (NHP) GLP toxicology data for CAP-002, its wholly owned first-in-class, intravenously (IV) administered investigational gene therapy for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). These data were the foundation for the Investigational New Drug (IND) application for CAP-002 that was recently cleared by the U.S. Food and Drug Administration (FDA). Capsida will deliver these data in an oral presentation today at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 13-17, 2025, in New Orleans and virtually.
The three-month cohort data from the NHP GLP toxicology study demonstrate dose-dependent brain-wide expression of STXBP1 and simultaneous detargeting of the liver and dorsal root ganglia (DRGs). CAP-002 was delivered as a single dose via IV infusion at 3.8E13 vg/kg, 5.9E13 vg/kg, and 7.4E13 vg/kg. There was a dose-dependent increase in average cargo RNA levels in the brain, with the 3.8E13 vg/kg dose of CAP-002 demonstrating a 207-fold increase over cargo RNA levels previously shown for 2.5E13 vg/kg of IV-delivered adeno-associated virus 9 (AAV9). Together with pharmacology data in a mouse model of STXBP1-DEE, these NHP GLP toxicology results show that all doses of CAP-002 tested have the potential to fully correct seizures and meaningfully correct cognitive and motor dysfunction in patients. The 3.8E13 vg/kg dose of CAP-002 also demonstrated robust 10x and 13x detargeting of liver and DRGs respectively, compared to a 2.5E13 vg/kg dose of AAV9. CAP-002 was well tolerated with no adverse clinical pathology or histopathology findings throughout the central nervous system, DRGs, or peripheral organs, including the liver.
CAP-002 is the first IV-administered, AAV blood brain barrier-crossing genetic medicine program entering a human clinical trial. CAP-002 is manufactured in Capsida's state-of-the-art wholly owned facility using a proprietary manufacturing process. Capsida received FDA Orphan Drug Designation in October 2024 and is now initiating study start-up activities for the SYNRGY Phase 1/2a clinical trial, with the first patient expected to be dosed in the third quarter of this year.
'These GLP toxicology data established the potential of CAP-002 to safely treat STXBP1-DEE and were a critical part of the data package to enable the FDA IND clearance of this first-in-class IV investigational gene therapy,' said Swati Tole, M.D., Chief Medical Officer of Capsida Biotherapeutics. 'Our focus is on initiating our Phase 1/2a SYNRGY clinical trial with the aim of providing a safe, disease-modifying treatment for STXBP1-DEE patients and their families.'
Presentation Details
Oral Presentation:
Abstracts can be found at https://annualmeeting.asgct.org/ and the presentation will be available under the 'Publications' section of the Capsida website.
About STXBP1-DEE
Syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE) is estimated to affect up to one in 26,000 births globally, equating to approximately 5,000 pediatric patients in the U.S. and Europe. The STXBP1 protein is present in every neuron and is essential for normal neurotransmission. Mutations in the STXBP1 gene are associated with early-onset seizures, severe developmental delay and intellectual disability, motor abnormalities, and a risk of sudden unexpected death in epilepsy (SUDEP). There are no approved treatments for STXBP1-DEE.
About Capsida Biotherapeutics
Capsida Biotherapeutics is a fully integrated next-generation genetic medicines company with a central nervous system (CNS) pipeline consisting of disease modifying and potentially curative treatments for rare and more common diseases across all ages. Capsida's wholly owned pipeline includes its first-in-class treatment for STXBP1 developmental and epileptic encephalopathy (STXBP1-DEE), which has received Investigational New Drug (IND) clearance to initiate clinical trials from the U.S. Food and Drug Administration (FDA). Capsida's pipeline also includes potential best-in-class treatments for Parkinson's disease associated with GBA mutations (PD-GBA) and Friedreich's ataxia (FA). The PD-GBA program is also on track to enter clinical development this quarter. In addition to its wholly owned programs, the Company has validating partnerships with AbbVie, Lilly, and CRISPR Therapeutics. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners and originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at Caltech. Visit us at www.capsida.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250514208408/en/
CONTACT: Media Contact
Greig Communications, Inc.
Kathy Vincent
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA LOUISIANA
INDUSTRY KEYWORD: HEALTH GENETICS CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Capsida Biotherapeutics
Copyright Business Wire 2025.
PUB: 05/14/2025 07:45 AM/DISC: 05/14/2025 07:44 AM
http://www.businesswire.com/news/home/20250514208408/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
2025 CrowdStrike Threat Hunting Report: Adversaries Weaponize and Target AI at Scale
AUSTIN, Texas & LAS VEGAS--(BUSINESS WIRE)--Black Hat USA 2025-- CrowdStrike (NASDAQ: CRWD) today released the 2025 Threat Hunting Report, highlighting a new phase in modern cyberattacks: adversaries are weaponizing GenAI to scale operations and accelerate attacks – and increasingly targeting the autonomous AI agents reshaping enterprise operations. The report reveals how threat actors are targeting tools used to build AI agents – gaining access, stealing credentials, and deploying malware – a clear sign that autonomous systems and machine identities have become a core part of the enterprise attack surface. CrowdStrike Threat Hunting Report Highlights Based on frontline intelligence from CrowdStrike's elite threat hunters and intelligence analysts tracking more than 265 named adversaries, the report reveals: Adversaries Weaponize AI at Scale: DPRK-nexus adversary FAMOUS CHOLLIMA used GenAI to automate every phase of its insider attack program. From building fake resumes and conducting deepfake interviews to completing technical tasks under false identities – AI-powered adversary tradecraft is transforming traditional insider threats into scalable, persistent operations. Russia-nexus adversary EMBER BEAR used GenAI to amplify pro-Russia narratives and Iran-nexus adversary CHARMING KITTEN deployed LLM-crafted phishing lures targeting U.S. and EU entities. Agentic AI Is the New Attack Surface: CrowdStrike observed multiple threat actors exploiting vulnerabilities in tools used to build AI agents, gaining unauthenticated access, establishing persistence, harvesting credentials, and deploying malware and ransomware. These attacks demonstrate how the agentic AI revolution is reshaping the enterprise attack surface – turning autonomous workflows and non-human identities into the next frontier of adversary exploitation. GenAI-built Malware Becomes Reality: Lower-tier eCrime and hacktivist actors are abusing AI to generate scripts, solve technical problems, and build malware – automating tasks that once required advanced expertise. Funklocker and SparkCat are early proof points that GenAI-built malware is no longer theoretical, it's already operational. SCATTERED SPIDER Accelerates Identity-Based, Cross-Domain Attacks: The group resurged in 2025 with faster and more aggressive tradecraft – leveraging vishing and help desk impersonation to reset credentials, bypass MFA, and move laterally across SaaS and cloud environments. In one incident, the group moved from initial access to encryption by deploying ransomware in under 24 hours. China-nexus Adversaries Drive Continued Surge in Cloud Attacks: Cloud intrusions rose 136%, with China-linked adversaries responsible for 40% of increased activity, as GENESIS PANDA and MURKY PANDA evaded detection through cloud misconfigurations and trusted access. 'The AI era has redefined how businesses operate, and how adversaries attack. We're seeing threat actors use GenAI to scale social engineering, accelerate operations, and lower the barrier to entry for hands-on-keyboard intrusions,' said Adam Meyers, head of counter adversary operations at CrowdStrike. 'At the same time, adversaries are targeting the very AI systems organizations are deploying. Every AI agent is a superhuman identity: autonomous, fast, and deeply integrated, making them high-value targets. Adversaries are treating these agents like infrastructure, attacking them the same way they target SaaS platforms, cloud consoles, and privileged accounts. Securing the AI that powers business is where the cyber battleground is evolving.' Additional Resources: Download the 2025 CrowdStrike Threat Hunting Report. Visit CrowdStrike's Adversary Universe for the internet's definitive source on adversaries. Listen to the Adversary Universe podcast to glean insights into threat actors and recommendations to amplify security practices. To learn more about the 2025 CrowdStrike Threat Hunting Report, read our blog, visit us online, or stop by the CrowdStrike Black Hat booth #2733. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.
Business Wire
39 minutes ago
- Business Wire
Legatum on Track for Initial Commitments of Over $US30 Million for New Collaborative Fund to Transform Crisis Relief
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Legatum, the private investment group with a twenty-year track record in collaborative philanthropy and humanitarian action, has today announced it is on track to secure over $US30 million in initial commitments for its latest philanthropic endeavour — the Resilio Fund, a pioneering initiative designed to transform crisis response by putting resources and decision-making into the hands of the affected communities. The Resilio Fund, which is the fourth collaborative fund launched by Legatum, follows a four-year pilot across seven countries, in which over 1000 micro-grants were distributed to communities by local NGOs, reaching more than 500,000 people. These grants enabled communities to rapidly restore essential services and build resilience against future shocks. From mending wells and clearing roads to distributing seeds and tools, the model has demonstrated speed, cost-efficiency, and, critically, has respected the dignity and agency of those affected. This announcement marks a significant milestone in the evolution of humanitarian funding models, with Legatum committing $10 million as Founding Donor, and three leading philanthropic institutions confirmed as Anchor Donors: the Vitol Foundation, UBS Optimus Foundation, and the Irene M Staehelin Foundation, with more to be announced shortly. Guy Cave, President of the Legatum Foundation, said, 'After years of discussion in the sector about shifting power to communities, we believe it's past time to act. The Resilio Fund embodies our conviction that those closest to crises are best placed to lead the response. We are proud to stand with a coalition of visionary donors who are backing this transformative approach.' The Fund's innovative model is based on the principle of survivor-and community-led crisis response. Grants are channelled to local NGOs, which in turn issue trust-based micro-grants to grassroots community groups. These groups, already taking action to help their community, use the funds flexibly to meet urgent needs — from purchasing emergency food and water to repairing vital infrastructure and securing livelihoods through agriculture and trade. Unlike much international, top-down humanitarian funding, which can be hampered by bureaucracy and external control, Resilio's approach champions trust, flexibility, and proximity. It acknowledges the capacity and courage of communities to respond to their own needs and supports them with the resources to do so effectively. Tom Hall, Global Head of Social Impact and Philanthropy and CEO, UBS Optimus Foundation Network, said, 'We are proud to be an anchor partner in the Resilio Fund, deepening our collaboration with Legatum. This partnership reinforces our commitment to community resilience by empowering local organisations and the communities they support to lead crisis response and recovery – a strategy that has proven effective through our emergency response portfolio.' Federico Motka, Head of Emergencies and Humanitarian Portfolio, Vitol Foundation, added, 'The Resilio Fund is setting a new benchmark for humanitarian response by putting local communities at the heart of crisis relief. By empowering hyper-local groups - those who are first to respond and best understand their own needs - Resilio will ensure aid is fast, effective, and rooted in dignity and agency. This approach not only delivers immediate support where it's needed most, but also strengthens the long-term resilience of communities, transforming the way the world responds to crises. At this critical time of the humanitarian reset the Resilio Fund shows us the way forward, ensuring that support reaches those who need it most, when they need it most.' Legatum confirmed that an inaugural CEO of the Resilio Fund will be announced in the coming days, signalling the next phase of development for the initiative. Discussions are also underway with additional prospective donors, with further announcements expected later this year. For more information about the Resilio Fund, or to enquire about becoming a donor, please visit About Legatum Legatum is an investment partnership that invests its capital and ideas in initiatives it believes will shape a better future. Since 2006, Legatum has supported a range of philanthropic initiatives, and founded three previous collaborative Funds: The END Fund formed to control and eliminate the five most common neglected tropical diseases by 2030. To date the Fund has directly impacted over 480 million lives. The Luminos Fund gives children excluded from school due to poverty, conflict or discrimination, a second chance at mainstream education. To date, it has supported more than 377,000 children to return to school. The Freedom Fund, co-founded with Walk Free Foundation and Humanity United, identifies and invests in the most effective community-led efforts to eradicate modern slavery. In the last nine years, the fund has helped liberate more than 30,000 people from slavery. For more information visit
Business Wire
39 minutes ago
- Business Wire
Motive Launches in the UK to Power Safer, Smarter, More Sustainable Fleet Operations with AI
LONDON--(BUSINESS WIRE)-- Motive, the AI-powered Integrated Operations Platform for the physical economy, today announced its launch in the United Kingdom. With the opening of a new London office and the appointment of regional vice president, Nyanya Joof, Motive will bring its AI-powered solutions for Driver Safety, Fleet Management, and Workforce Management to businesses in the UK with complex physical operations. The company's expansion builds on its strong North American adoption and supports fleets across industries such as transportation, construction, field services, energy, utilities, and the food and beverage sector. 'Motive's mission is to empower the people who run physical operations with tools to make their work safer and more productive,' said Shoaib Makani, CEO and Co-founder of Motive. 'We're excited to bring that mission to the UK at a time when AI can make a meaningful difference—helping businesses reduce road collisions, lower costs, automate manual work, and accelerate the transition to more sustainable operations. Our platform is already delivering measurable results around the world, and we look forward to unlocking that same value for businesses in the UK.' Businesses with fleets in the UK face growing challenges, including a projected shortage of 200,000 Heavy Goods Vehicle (HGV) drivers over the next five years; rising fuel, insurance, and maintenance costs; and heightened road casualties following nearly 130,000 incidents in 2024 alone. At the same time, businesses are under pressure to improve sustainability and transition to electric vehicles (EVs), while managing outdated, siloed systems that limit operational visibility and agility. To help address these difficulties, Joof will lead Motive's regional strategy, hiring, and go-to-market (GTM) execution. With over 15 years of experience scaling GTM teams across Europe, including leadership roles at WeWork, she will oversee how Motive supports UK customers with tools designed to address their most urgent safety, workforce, and cost-related challenges. Motive's AI-powered platform helps businesses in the UK: Protect workers, improve safety, and boost morale: Motive's Driver Safety solution, including its use of precise AI accuracy, detects risky behaviours, such as mobile phone use and stop sign violations, to help prevent accidents before they happen. Businesses can exonerate drivers, reinforce safety standards through real-time coaching, and recognise safe driving, ultimately improving retention and morale. Optimize spend: Motive's Fleet Management solution helps businesses reduce insurance premiums by an average of 21%, lower maintenance spend, and improve fuel efficiency. Its AI-driven visibility into vehicle health, routing, and utilisation supports faster decision-making and more efficient operations—delivering measurable savings. Save time and increase productivity: Motive's Workforce Management solution automates manual tasks such as scheduling, time tracking, payroll, training, and documentation, reducing administrative overhead and freeing teams to focus on higher-value work. The Motive Driver App also simplifies roadside inspections and compliance documentation, removing the need for paper-based systems. Navigate the green transition: Motive helps businesses adapt to rising regulatory and sustainability demands, such as the UK's 2030 Zero Emission Vehicle Mandate by managing the shift to EVs with tools tailored for mixed-fleet environments. Its EV forecasting software, fuel-efficient routing, and digitised workflows enable teams to plan vehicle charging, optimise routes, and reduce downtime. EVs can cost up to 25% more to repair and take 14% longer to service than petrol vehicles, making Motive's predictive maintenance and AI-powered safety capabilities critical for reducing electrification costs and maintaining fleet readiness. These capabilities are further strengthened by Motive's recent acquisition of InceptEV, an advanced battery intelligence software startup. 'Motive's AI-powered platform is transforming how we manage fleet safety across parts of our U.S. operations—giving us the opportunity to prevent collisions, protect drivers, and respond faster with near real-time insights,' said Zach Spengler, Director of EHS at ABM Aviation. "There's clear potential for businesses in the UK and beyond to benefit from the technology to enhance safety, streamline maintenance, and improve fuel efficiency at scale.' Additional Resources: About Motive Motive empowers the people who run physical operations with tools to make their work safer, more productive, and more profitable. For the first time, safety, operations, and finance teams can manage their workers, vehicles, equipment, and fleet-related spend in a single system. Motive serves nearly 100,000 customers from small businesses to Fortune 500 enterprises such as Halliburton, KONE, Komatsu, NBC Universal, and Maersk across a wide range of industries, including transportation and logistics, construction, energy, field service, manufacturing, agriculture, food and beverage, retail, waste services, and the public sector. Visit to learn more.
